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OBJECTIVES: To investigate long-term prospective asso-
ciations between a range of measurements of hypertensive
status in midlife and cognitive impairment 20 years later.
DESIGN: Cohort study.
SETTING: Two areas (Southall and Brent) of northwest
London.
PARTICIPANTS: Survey samples of a multiethnic popula-
tion (European, African Caribbean, South Asian) aged 40
to 67 were followed up 20 years later.
MEASUREMENTS: Comprehensive cardiovascular assess-
ments were performed at baseline, including measurements
of resting blood pressure (BP) and, in a subsample, ambu-
latory BP. At follow-up, a battery of cognitive assessments
was administered, and a composite outcome was derived,
with impairment defined as the lowest 10% within each
ethnic group. Logistic regression models were used to
investigate associations with prior measures of hyperten-
sive status.
RESULTS: In 1,484 participants at follow-up, cognitive
impairment showed significant U-shaped associations with
baseline diastolic BP (DBP) and mean arterial pressure
(MAP; strongest for those aged ≥50 at baseline), indepen-
dent of a range of covariates, but no associations were
found with systolic BP or pulse pressure. Cognitive impair-
ment was also associated with antihypertensive medication
use and higher evening ambulatory DBP at baseline. No
substantial differences in strengths of association were
found between ethnic groups.
CONCLUSION: Low and high DBP and MAP were asso-
ciated with cognitive impairment 20 years later. Higher
evening DBP on ambulatory monitoring was also associ-
ated with greater risk. J Am Geriatr Soc 61:1489–1498,
2013.
Key words: cognitive impairment; hypertension; blood
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Cognitive impairment is a matter of increasing publichealth importance with rapid demographic aging.
Hypertension is a risk factor for cognitive impairment and
is important because of its high prevalence and potential
for modification. Relationships between blood pressure
(BP) levels or exposure to hypertension and cognitive
impairment or dementia as outcomes have been reviewed
extensively,1 and findings from cross-sectional studies and
short-duration prospective studies have been heteroge-
neous, including associations with high BP, with low BP,
and with high and low BP (U-shaped relationship). The
few cohort studies with longer than a 10-year interval
between BP measurement and cognitive examination have
found that higher midlife BP is incrementally associated
with greater risk of later dementia or cognitive impair-
ment, although findings have been inconsistent in terms of
the component of BP most associated with cognitive out-
comes and the role of treated hypertension as a risk
factor.2–6
Other measures of hypertension have received much
less research. Pulse pressure (PP), a proxy measure of arte-
rial stiffness associated with greater risk of cardiovascular
events,7 has been found to be associated with dementia
and cognitive decline or impairment when measured in late
life,8–10 but few, if any, data have been reported on midlife
PP or mean arterial pressure (MAP) in relation to later
cognitive outcomes. Ambulatory BP is a better predictor of
cardiovascular events and adverse outcomes than clinic BP
measurement,11 and a recent study found this also to be
true for 24-hour SBP in relation to white matter hyperin-
tensity volume and cognitive decline as outcomes.12
From the *King’s College London (Institute of Psychiatry), †National
Heart and Lung Institute, Imperial College London, London, UK;
‡Departments of Psychiatry, §Psychobiology, Universidade Federal de São
Paulo, São Paulo, Brazil; kMedical Research Council Study of Health and
Development, London; and #School of Health, University of Central
Lancashire, Preston, UK.
Address correspondence to Dr. Robert Stewart, Section of Epidemiology
(Box 60), Institute of Psychiatry, De Crespigny Park, London SE5 8AF,
UK. E-mail: r.stewart@iop.kcl.ac.uk
DOI: 10.1111/jgs.12416
JAGS 61:1489–1498, 2013
© 2013, Copyright the Authors
Journal compilation © 2013, The American Geriatrics Society 0002-8614/13/$15.00
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Finally, urinary albumin excretion is an indicator of micro-
vascular disease 13 but has received little attention as a
possible mechanism for the effect of hypertension on cog-
nitive function. The aim of this analysis was to investigate
associations between comprehensive measures of midlife
hypertension and later-life cognitive impairment.
METHODS
Study Design and Participants
The Southall and Brent Revisited (SABRE) Study was
designed to follow up cardiovascular outcomes in commu-
nity samples of European, South Asian, and African-
Caribbean residents who had originally been recruited in
the London boroughs of Brent and Southall in 1988 to
1991. Baseline surveys had investigated cardiometabolic
risk in residents aged 40 to 69 from three ethnic groups
(European, n = 2,346; South Asian, n = 1,710; and Afri-
can Caribbean, n = 801) and have been described previ-
ously.14 Participants were recruited from primary care lists
and industrial workforces, with response rates ranging
from 58% to 71%. Because of the nature of the recruit-
ment waves,14 there was a male preponderance in the
baseline sample. All South Asian and African-Caribbean
participants were first-generation migrants, most of whom
had moved to the United Kingdom in the 1950s and
1960s. Exclusion criteria were cancer and renal failure,
severe disability, and severe psychiatric disturbance.
The SABRE follow-up study approached surviving
participants still living in England or Wales. Participants
were traced using the UK National Health Service tracing
system in 2008, 20 years after baseline, and data collection
took place between 2008 and 2011. Home assessments
were attempted for consenting participants unable or
unwilling to attend clinic. All participants gave written
informed consent. Approval for the baseline study was
obtained from Ealing, Hounslow and Spelthorne, Parkside,
and University College London research ethics committees
and at follow-up from St Mary’s Hospital Research Ethics
Committee (ref. 07/H0712/109).
Baseline Assessments
Participants were asked to complete a health and lifestyle
questionnaire at baseline. Health examinations were
conducted after an overnight fast and included blood sam-
ples taken after fasting and after a 75-g glucose load. Bra-
chial BP was measured at rest according to a standard
protocol using a random zero sphygmomanometer.15 Par-
ticipants were seated for 5 minutes before measurement on
the right arm. Systolic and diastolic BP (SBP and DBP)
were recorded as the average of two readings with an
interval of at least 1 minute. Hypertensive treatment
was ascertained from the participant questionnaire.
African-Caribbean and European participants recruited to
the Brent study center were also considered for ambulatory
BP monitoring. Every other participant whose clinic BP
was less than 140/90 mmHg and who was not known to
have hypertension and all of those whose clinic BP was
140/90 mmHg or greater were offered ambulatory moni-
toring (TM2420, Takeda, Tokyo, Japan) for 24 hours
after screening. The monitors were programmed to mea-
sure BP every 15 minutes during the day (8 a.m. to
10 p.m.) and every half hour at night.
Covariates
Cardiovascular disease was defined on the basis of major
Q waves on electrocardiogram at baseline or self-reported
coronary heart disease or stroke. Height and weight were
measured,15 body mass index (BMI) was calculated, and
obesity was defined as a BMI greater than 30.0 kg/m2.
Fasting blood samples were taken and glucose and choles-
terol levels assayed. Diabetes mellitus was ascertained from
self-report and retrospective application of World Health
Organization (WHO) 1999 criteria.16 Albumin excretion
rate (AER) was established from timed overnight urine col-
lections using immunoturbidimetry.17 Smoking status was
ascertained by questionnaire and coded as never, current,
or previous, and alcohol consumption was coded as less
than weekly, one to two times per week, and daily or
almost daily.
Follow-Up Assessment
Trained staff conducted cognitive assessments that lasted
approximately 30 minutes early on the day of clinic atten-
dance or home visit to avoid fatigue. The test battery
consisted largely of tests successfully used in previous cross-
cultural settings from the 10/66 Dementia in Developing
Countries research program18 and a previous prospective
study of African-Caribbean elderly adults in London19 and
assessed the domains of global function (Community
Screening Instrument for Dementia (CSID) cognitive assess-
ment20), immediate and delayed verbal recall (Consortium
to Establish a Registry for Alzheimer’s Disease 10-word list
learning task21), verbal fluency (animal naming22), attention
and mental flexibility (Color Trailmaking tests23), attention
and immediate recall (forward and backward digit span24),
and delayed visual recall (WHO gnostic assessments25). To
accommodate South Asian participants who were not confi-
dent in English, a bilingual psychiatric nurse with expertise
in dementia carefully translated the test instruments into
Punjabi, with independent back-translation and review by a
panel of clinicians with experience working closely with
older people with dementia of South Asian ethnicity to
ensure that they were as culturally fair as possible. A bilin-
gual interviewer administered these assessments.
A composite measure of cognitive impairment was
derived from this battery by standardizing individual test
scores into z-scores (taking into account the distribution
for the given ethnic group, subtracting the group mean
from individual scores, and dividing each by the group
standard deviation). These z-scores were then averaged for
each participant to create a single score, an exploratory
principal components analysis having previously estab-
lished that there was a single-factor solution for each eth-
nic group in (data not shown). Stratifying the sample
according to ethnicity, cognitive impairment as a binary
outcome was defined according to a cutoff as close as
possible to the 10th percentile for the group distribution.
These composite variables for each of the three ethnic
groups were combined to create a single variable for the
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sample as a whole (defining the 10% most cognitively
impaired participants based on the distribution of scores
within their ethnic group). For the 15.8% participants
who did not have a complete set of cognitive data, average
z-scores were calculated using only the tests they had com-
pleted, provided they had completed at least four, includ-
ing the CSID. Impairment was defined using identical 10th
percentile cutoffs established when those who had the
complete set of cognitive outcomes were identified as
impaired or not impaired. This was to take into account
ethnic group differences in cognition as much as possible.
Finally, test-specific cognitive impairment variables were
defined for secondary analyses, based on cutoffs closest to
10th percentiles, considering the distributions within each
ethnic group and categorizing participants accordingly.
Statistical Analysis
Primary independent variables consisted of SBP and DBP.
PP was calculated as SBP minus DBP and MAP was calcu-
lated as DBP + 1/3 PP. These variables and mean SBP and
DBP at the three time points were divided into quintiles
for initial analyses, and associations were investigated with
cognitive impairment as the principal dependent variable.
Multivariable analyses were performed using logistic
regression, entering BP measures as continuous variables
and then introducing a quadratic term. Crude associations
were then adjusted for demographic factors (baseline age,
interval between baseline and follow-up examinations,
sex, education, and ethnicity), followed by a multivariable
model with all covariates entered. Interactions between BP
and ethnicity were tested using likelihood ratios in the full
multivariable model. Because AER data were available
only for a subsample, the analyzed sample was restricted
to those with full data before investigating the effect of
adjusting for this variable. Multivariable analyses of
hypertensive treatment receipt as a binary variable were
performed in the same way, including likelihood ratio tests
for the interaction between treatment and ethnicity, as
were those of ambulatory BP measurements (but without
any interaction tests, because of the smaller sample size).
Post hoc analyses were also performed stratifying accord-
ing to age (above and below median) and hypertensive
treatment. As mentioned, cognitive impairment had been
reconstructed as a variable in those with incomplete data;
sensitivity analyses restricted to the subsample with a full
set of cognitive data were performed, but no substantial
differences were found (data not shown). Secondary analy-
ses were performed reassessing significant factors identified
in primary analyses in relation to identically defined
impairments for each of the individual component tests as
separate outcomes. To investigate potential influences of
attrition between baseline and follow-up examinations, a
sensitivity analysis was performed using inverse probabil-
ity weighting. These weights were calculated using logistic
regression after estimation for the full baseline sample
excluding those who subsequently died and entering all
baseline covariates as predictors of participants’ presence
or not in the final analyzed sample (successful follow-up
with sufficient cognitive data for analysis). Primary analy-
ses were then repeated, entering these postestimation
probability coefficients as inverse weights (in effect,
applying additional weighting to participants with charac-
teristics that predicted attrition in the baseline sample).
RESULTS
Of 4,857 participants at baseline, 1,101 died, leaving
3,756. Of these, 306 did not respond, 241 had no UK
address found, and 82 had emigrated. Of 3,433 traceable
participants, 2,129 (62.0%) were directly followed up with
20 years later, and 1,484 of these had sufficient cognitive
data to be included in the analysis (1,429 examined in
clinic, 55 at home; 692 European, 551 South Asian, and
241 African Caribbean). Altogether, 172 (11.6%) partici-
pants with cognitive data were defined as having cognitive
impairment. Compared to the baseline sample, those
examined for cognitive function at follow-up were younger
than the baseline sample (49.9  6.2 and 52.4  6.9,
respectively) and had higher education (<10 years of edu-
cation, 16.1% and 26.5%, respectively), but there was no
substantial difference in sex distribution (female, 23.9%
and 24.7%, respectively) or mean BP at baseline (121/78
and 125/79 mmHg, respectively). The range of intervals
between baseline and follow-up examinations was 17 to
23 years (median 20 years).
As shown in Table 1, in unadjusted analyses, cognitive
impairment was associated with the baseline characteristics
of older age, female sex, lower education, diabetes mellitus,
microalbuminuria, and higher BMI. Cognitive impairment
was also associated with hypertension treatment at baseline,
and significant heterogeneity was seen across quintiles of SBP
and DBP, with a significant linear trend for SBP, PP, and
MAP but not DBP. In terms of ambulatory BP in the subsam-
ple of 117 participants in whom these measurements were
taken, there was a significant linear association between
evening and nighttime ambulatory SBP and DBP and cogni-
tive impairment. Figure 1 illustrates the relationship between
BP quintiles at baseline and cognitive impairment at follow-
up. Risk of cognitive impairment increased monotonically
across the SBP and PP distributions, but the associations with
DBP andMAPwere U-shaped.
From analyses summarized in Table 2, the linear associ-
ations between SBP, PP, and cognitive impairment were
attenuated after adjustment for demographic factors,
although subsequent adjustment for other covariates had lit-
tle further effect. An interaction term with ethnicity fell
below statistical significance for SBP (likelihood ratio test
chi-square (v2) = 5.74, P = .06) and for PP (v2 = 3.39,
P = .18). Logistic regression analyses of DBP and MAP
showed significant nonlinear relationships with cognitive
impairment, with linear and quadratic terms remaining sig-
nificant in the fully adjusted models and little changed after
further adjustment for AER. No interactions with ethnicity
were found for either variable (DBP, v2 = .65, P = .72;
MAP, v2 = 1.84, P = .40). With post hoc stratification
according to baseline age, the associations between DBP and
MAP and cognitive impairment were strongest in the older
half of the sample (50–67; for DBP, fully adjusted odds ratio
(OR) = 0.06, 95% confidence interval (CI) = 0.01–0.41 lin-
ear, OR = 1.20, 95% CI = 1.07–1.34 quadratic; for MAP:
OR = 0.08, 95% CI = 0.01–0.57 linear, OR = 1.14, 95%
CI = 1.04–1.26 quadratic) and were not significant in
the younger half (40–49; for DBP: OR = 0.33, 95%
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Table 1. Baseline Exposure and Unadjusted Associations with Cognitive Impairment at Follow-Up
Midlife Exposure N Cognitive Impairment at Follow-Up,% Chi-Square (Degrees of Freedom), P-Value
Age
40–49 755 6.1 45.33 (1), <.001
50–67 729 17.3
Sex
Male 1,129 10.5 5.08 (1), .02
Female 355 14.9
Duration of education, years
<10 234 29.1 97.84 (1), <.001
≥10 1,220 7.2
Diabetes mellitus
Absent 1,359 10.9 7.71 (1), .005
Present 125 19.2
Microalbuminuria
Absent 889 10.9 17.09 (1), <.001
Present 40 32.5
Cardiovascular disease
Absent 1,430 11.4 1.41 (1), .23
Present 54 16.7
Body mass index, kg/m2
<30.0 1,308 10.9 5.95 (1), .01
≥30.0 175 17.1
Alcohol frequency per week
<1 682 13.3 2.73 (1), .10
1–2 440 8.9
≥Almost daily 349 10.6
Smoking
Never 876 12.0 0.41 (2), .81
Previous 264 11.0
Current 341 10.9
Hypertension treatment
Present 129 21.7 14.11 (1), <.001
Absent 1,355 10.6
SBP, mmHg
82–108 306 9.8 8.19 (1), .004
109–116 324 9.9
117–123 277 10.1
124–134 302 10.6
135–197 275 18.2
DBP, mmHg
39–70 348 12.4 1.60 (1), .21
71–75 281 10.0
76–80 300 9.7
81–87 282 8.9
88–133 273 17.2
Pulse pressure, mmHg
17–34 302 8.3 10.35 (1), .001
35–39 307 11.4
40–44 284 8.5
45–51 299 12.7
52–106 292 17.1
Mean arterial pressure, mmHg
61–82 302 11.3 6.24 (1), .01
83–88 292 7.9
89–94 311 11.3
95–101 284 9.9
102–150 295 17.6
Mean ambulatory SBP, mmHg, 9–11 a.m.
88–116 24 4.2 1.57 (1), .21
117–129 23 13.0
130–137 24 12.5
138–150 23 13.0
151–182 23 17.4
(Continued)
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CI = 0.05–2.25 linear, OR = 1.08, 95% CI = 0.96–1.21
quadratic; for MAP: OR = 0.22, 95% CI = 0.03–1.89 lin-
ear, OR = 1.09, 95% CI = 0.98–1.21 quadratic). The lower
DBP component of the nonlinear association was stronger in
those who were not receiving antihypertensive treatment at
baseline (linear term OR = 0.21, 95% CI = 0.05–0.80; qua-
dratic term OR = 1.11, 95% CI = 1.02–1.20) than in those
receiving antihypertensive treatment (linear termOR = 0.01,
95% CI = 0.00–5.66; quadratic term OR = 1.43, 95%
CI = 0.96–2.14).
Table 3 summarizes analyses of the association
between hypertensive treatment at baseline and cognitive
impairment at follow-up. In summary, although attenu-
ated by adjusting for age and sex, this association per-
sisted after adjusting for covariates and after further
adjustment for AER. No significant interaction with eth-
nicity was found (v2 = .11, P = .94), and post hoc adjust-
ment for DBP and MAP made little difference (data not
shown).
Sensitivity analyses using inverse probability weighting
(to take attrition between baseline and follow-up interviews
into account) revealed similar findings. In fully adjusted
models (Model 2 in Tables 2 and 3), ORs for cognitive
impairment were as follows: SBP, OR = 1.08 (95%
CI = 0.95–1.23), DBP linear, OR = 0.12 (95% CI = 0.03–
0.54), DBP quadratic, OR = 1.15 (95% CI = 1.05–1.26),
PP, OR = 0.93 (95% CI = 0.79–1.10), MAP linear, OR =
0.10 (95% CI = 0.02–0.57), MAP quadratic, OR = 1.13
(95% CI = 1.04–1.24), antihypertensive treatment, OR =
2.00 (95% CI = 1.16–3.42).
Table 4 displays logistic regression analyses from the
subsample that underwent ambulatory BP monitoring. No
associations were found with later cognitive function for
average morning or nighttime BP, but there were linear
associations between evening SBP and DBP and likelihood
of cognitive impairment that were largely unaltered after
individual adjustments for covariates, although evening
SBP was no longer significant in the fully adjusted model.
Further adjustments for resting DBP or MAP or for antihy-
pertensive treatment had little effect on the association
between evening DBP and cognitive impairment (data not
shown).
Table S1 displays logistic regression analyses of cogni-
tive impairment according to individual tests as dependent
variables (with impairment on each defined on the basis of
a score within the lowest 10% of the distribution within
each ethnic group). In summary, most of the associations
were strongest for verbal fluency as an outcome, particu-
larly the U-shaped relationships with DBP and MAP. Anti-
hypertensive treatment was most strongly associated with
impaired immediate verbal and visual recall.
DISCUSSION
Using data from a long-running multiethnic cohort study,
associations between current cognitive impairment and
Table 1 (Contd.)
Midlife Exposure N Cognitive Impairment at Follow-Up,% Chi-Square (Degrees of Freedom), P-Value
Mean ambulatory DBP, mmHg, 9–11 a.m.
51–72 24 12.5 0.81 (1), .37
73–81 24 4.2
82–88 23 8.7
89–99 24 20.8
100–131 22 13.6
Mean ambulatory SBP, mmHg, 5–7 p.m.
79–113 32 0 12.48 (1), <.001
114–124 29 6.9
125–134 32 6.3
135–144 29 27.6
145–195 30 23.3
Mean ambulatory DBP, mmHg, 5–7 p.m.
43–73 33 6.1 8.98 (1), .003
74–81 28 0
82–88 31 9.7
88–95 30 23.3
95–125 30 23.3
Mean ambulatory SBP, mmHg, 3–5 a.m.
68–95 30 6.7 4.84 (1), .03
96–105 28 7.1
106–115 30 10.0
116–125 29 13.8
126–178 28 25.0
Mean ambulatory DBP, mmHg, 3–5 a.m.
41–60 31 12.9 2.02 (1), .16
61–67 32 3.1
68–74 26 3.9
75–81 27 29.6
82–105 29 13.8
SBP = systolic blood pressure; DBP = diastolic blood pressure.
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markers of hypertensive disease 20 years earlier were
investigated. In summary, an independent U-shaped associ-
ation was found with resting DBP and MAP levels (cogni-
tive impairment associated with high and low levels) and
independent associations with midlife use of antihyperten-
sive agents and with higher evening DBP in those who
underwent ambulatory BP monitoring. The U-shaped asso-
ciations with resting DBP and MAP were more prominent
in older than younger participants. Considering potential
underlying mechanisms, resting PP (as a marker of arterial
stiffness) showed little evidence of association, and AER
(as a measure of small vessel disease) did not have any
substantial influence on the associations of interest. The
associations did not vary substantially between ethnic
groups.
Strengths of the study were the 20-year interval
between exposure and outcome and comprehensive assess-
ment of BP at baseline, allowing examination of a variety
of different features of hypertension as exposures. Mea-
sures of ambulatory BP were only made in European and
African-Caribbean participants and were therefore not rep-
resentative of the sample at baseline, although they are
unlikely to be biased with respect to their associations
with cognitive function 20 years later. Cognitive assess-
ment was comprehensive and used procedures that had
been specifically designed for their cross-cultural applicabil-
ity, in particular, the CSID, which has received substantial
international evaluation.17 Weaknesses of this study
include limited statistical power in some respects, particu-
larly for stratified analyses. The sample examined should
also be considered to be relatively healthy survivors consti-
tuting a small proportion of the original participants,
although those with and without cognitive impairment
were drawn from the same source (survivors from the ori-
ginal cohort), and a sensitivity analysis using inverse prob-
ability weighting to account for differential attrition did
not meaningfully alter findings. Hypertension and cogni-
tive impairment are predictors of mortality, so survival
effects would more likely have obscured than exaggerated
associations. A large number of covariates were consid-
ered, although residual confounding cannot be excluded
absolutely. There was also no baseline information on cog-
nitive function and therefore no means of measuring cogni-
tive decline. Finally, no attempt was made to test
mediating pathways, so measures of health status at
follow-up were not considered as covariates.
The most consistent findings relating BP levels to cog-
nitive impairment in later life have arisen from samples
followed for at least 10 years. The findings of the current
study that hypertension was associated with cognitive
impairment 20 years later are in keeping with this litera-
ture, although other findings of worse late-life cognitive
function associated with progressively higher midlife DBP 3
differ from those of the current study, in which a
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Figure 1. Prevalence (%) of cognitive impairment at follow-up according to quintile of systolic, diastolic, pulse, and mean arte-
rial blood pressure at baseline.
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U-shaped relationship was found. Other studies of cogni-
tive function with BP ascertainment at least 10 years ear-
lier have reported associations with high midlife SBP
(≥160 vs <110 mmHg) in men,26 with progressively higher
midlife SBP in people who had not received antihyperten-
sive treatment,2 with persistently high SBP (≥140 mmHg)
over a 38-year period, and with high SBP (≥160 vs
<140 mmHg).4 In the Framingham Offspring cohort study,
midlife hypertension was specifically associated with worse
late-life executive function in addition to progression of
white matter hyperintensities on magnetic resonance imag-
ing.27 Findings from studies with dementia as an outcome
include associations between high midlife SBP and DBP
(≥160/95 mmHg) in men and dementia and AD, although
only in those not previously taking antihypertensive
agents,28 and an association between midlife high SBP
(≥160 vs <140 mmHg) but not high DBP and AD.29
Therefore, although hypertension is implicated in late-life
cognitive impairment, there is still a substantial level of
controversy around what components of BP are most
important and in what subgroups.
U-shaped associations between BP and cognitive
impairment are not uncommonly found, and there is ample
evidence of an exaggerated decline in BP (particularly SBP)
preceding the clinical onset of dementia.1 It is less usual to
find a U-shaped relationship over a 20-year interval, as
described here for DBP and MAP. The greater risk in those
with lower pressures is unlikely to represent a secondary
effect of neurodegeneration (often assumed to underlie
more-contemporaneous associations between lower BP and
cognitive impairment). Low BP might reflect atheroscle-
rotic disease, or it might be a longstanding feature by
which the individual is rendered vulnerable to episodes
of hypoperfusion. It might also be a marker of a
more-general frailty syndrome that predisposes to later
cognitive impairment. The apparently stronger associations
in older than younger participants at baseline supports
this, although it requires replication. The association with
lower DBP appeared stronger in people not taking antihy-
pertensive agents and was therefore not likely to be iatro-
genic in nature. Finally, the relationships were stronger for
verbal fluency than memory. Although Type 1 statistical
error is possible because this association was one of several
exploratory analyses, this stronger association with verbal
fluency may be consistent with subcortical damage second-
ary to cerebrovascular disease causing impairment in exec-
utive function rather than memory.
Fewer data have been published on midlife PP than on
SDB and DBP as an exposure for late-life cognitive impair-
ment. The Women’s Health Study found a five times
greater likelihood of impairment on a measure of executive
function in women with PP of 84 mmHg or greater than
in women aged 76 to 80 with PP less than 68 mmHg and
twice the incidence of impairment on immediate recall in
participants aged 70 to 75 with PP of 71 mmHg than in
those with PP less than 68 mmHg.10 The Kungsholmen
study found a U-shaped relationship between PP and
dementia in women aged 75 and older.8 These studies
measured a potentially much later stage of vascular pathol-
ogy in older age groups, but considerably less is known
about the role of midlife PP in relation to later cognitive
impairment. SBP is reported to increase with age, whereasT
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DBP increases up to aged 50 to 59 and then begins to
decline so that PP increases in later life.30 This may
explain why the current study found little evidence of mid-
life PP as an independent predictor of later cognitive
impairment. Similarly, the Honolulu Asia Aging study
found no association between PP in midlife and incidence
of dementia in later life.31 One possible explanation is that
PP is not important in the etiology of cognitive impair-
ment, a second is that this only becomes important closer
to the development of the outcome, and a third is that
people with higher PP in midlife who survive to late life
are healthy in other respects, masking associations with
later cognition. Midlife AER did not appear to play a sub-
stantial role in the association between BP and cognition,
even though baseline microalbuminuria was associated
with cognitive impairment.
The findings on ambulatory BP are novel in terms of
the length of follow-up between exposure and outcome.
Evening BP was more strongly associated with cognitive
impairment than morning and nocturnal measurements.
Previous research32 has found high nocturnal SBP in older
adults (mean age 71),33 lack of a nocturnal dip,34 and
exaggerated variability in very elderly adults 35 to be asso-
ciated with cognitive impairment and dementia. The
cohort in the current study was younger at the time of
ambulatory measurement, and although some evidence of
an association between nocturnal BP and later-life cogni-
tive impairment was found, this disappeared after adjust-
ment for age and sex. Mean resting BP might
underestimate an additional influence of BP variability,
although whether there are particular high-sensitivity peri-
ods during the day or night remains to be established. An
important consideration is that the timing of bed rest influ-
enced evening BP, and other factors might have con-
founded this association, which would require further
investigation.
If midlife BP is associated with later-life cognitive
impairment and subsequent dementia, management of BP
in midlife could have important public health implications
in terms of prevention. Several trials have been conducted
of BP lowering and cognitive outcomes,36–41 although only
the Systolic Hypertension in Europe Study found a
Table 3. Logistic Regression Analyses for Cognitive
Impairment at Follow-Up in Participants Undergoing
Hypertensive Treatment at Baseline Compared with All
Other Participants
Model N
Odds Ratio (95% Confidence
Interval), P-Value
Unadjusted 1,484 2.33 (1.48–3.67), <.001
1 (demographic
adjustments)
1,454 1.71(1.02–2.86), .04
2 (fully adjusted) 1,431 1.92 (1.13–3.25), .01
2 in participants
with AER data
895 2.15 (1.13–4.09), .02
2 plus AER 895 2.11 (1.10–4.03), .02
Model 1: adjusted for age at follow-up, interval between baseline and fol-
low-up, sex, education, ethnicity.
Model 2: adjusted for Model 1 covariates plus smoking, alcohol intake,
total cholesterol level, cardiovascular disease, obesity, diabetes mellitus.
AER = albumin excretion rate.
T
a
b
le
4
.
L
o
g
is
ti
c
R
eg
re
ss
io
n
A
n
a
ly
se
s
R
ep
re
se
n
ti
n
g
fo
r
C
o
g
n
it
iv
e
Im
p
a
ir
m
en
t
p
er
1
0
-m
m
H
g
In
cr
em
en
t
in
E
a
ch
A
m
b
u
la
to
ry
B
lo
o
d
P
re
ss
u
re
M
ea
su
re
m
en
t
in
th
e
S
u
b
sa
m
p
le
(1
1
7
A
fr
ic
a
n
-C
a
ri
b
b
ea
n
a
n
d
E
u
ro
p
ea
n
P
a
rt
ic
ip
a
n
ts
)
in
W
h
ic
h
T
h
is
W
a
s
M
ea
su
re
d
M
o
d
e
l
M
o
rn
in
g
(9
–1
1
a
.m
.)
E
v
e
n
in
g
(5
–7
p
.m
.)
N
ig
h
t
(3
–5
a
.m
.)
n
S
B
P
D
B
P
n
S
B
P
D
B
P
n
S
B
P
D
B
P
O
R
(9
5
%
C
I)
,
P
-V
a
lu
e
O
R
(9
5
%
C
I)
,
P
-V
a
lu
e
O
R
(9
5
%
C
I)
,
P
-V
a
lu
e
U
na
dj
us
te
d
11
7
1.
19
(0
.9
1–
1.
56
),
.2
1
1.
09
(0
.7
5–
1.
59
),
.6
5
15
2
1.
52
(1
.1
6–
1.
97
),
.0
02
1.
67
(1
.1
3–
2.
46
),
.0
1
14
5
1.
31
(1
.0
0–
1.
72
),
.0
49
1.
40
(0
.9
5–
2.
08
),
.0
9
1
(d
em
og
ra
ph
ic
ad
ju
st
m
en
ts
)
11
7
1.
05
(0
.7
6–
1.
44
),
.7
7
0.
92
(0
.6
0–
1.
40
),
.6
9
15
2
1.
38
(1
.0
2–
1.
85
),
.0
4
1.
94
(1
.1
8–
3.
20
),
.0
09
14
5
1.
22
(0
.9
0–
1.
65
),
.2
0
1.
35
(0
.8
5–
2.
14
),
.2
0
2
(f
ul
ly
ad
ju
st
ed
)
11
2
1.
02
(0
.6
6–
1.
58
),
.9
1
0.
91
(0
.4
5–
1.
81
),
.7
8
14
5
1.
29
(0
.8
8–
1.
87
),
.1
9
2.
97
(1
.2
0–
7.
33
),
.0
2
13
9
1.
26
(0
.7
9–
2.
00
),
.3
3
1.
76
(0
.9
0–
3.
42
),
.1
0
2
in
pa
rt
ic
ip
an
ts
w
ith
A
ER
da
ta
91
1.
24
(0
.6
9–
2.
22
),
.4
7
1.
37
(0
.5
7–
3.
27
),
.4
8
11
2
1.
93
(1
.0
5–
3.
54
),
.0
3
3.
19
(1
.1
3–
9.
01
),
.0
3
10
8
1.
04
(0
.6
0–
1.
79
),
.8
9
1.
92
(0
.8
7–
4.
24
),
.1
0
2
pl
us
A
ER
91
1.
02
(0
.5
3–
1.
98
),
.9
5
1.
13
(0
.4
4–
2.
88
),
.8
0
11
2
1.
71
(0
.8
9–
3.
26
),
.1
1
2.
87
(0
.8
8–
9.
37
),
.0
8
10
8
0.
82
(0
.4
4–
1.
55
),
.5
4
1.
64
(0
.7
3–
3.
71
),
.2
3
M
o
d
el
1
:
a
d
ju
st
ed
fo
r
a
g
e
a
t
fo
ll
o
w
-u
p
,
in
te
rv
a
l
b
et
w
ee
n
b
a
se
li
n
e
a
n
d
fo
ll
o
w
-u
p
,
se
x
,
ed
u
ca
ti
o
n
,
et
h
n
ic
it
y
.
M
o
d
el
2
:
a
d
ju
st
ed
fo
r
M
o
d
el
1
co
v
a
ri
a
te
s
p
lu
s
sm
o
k
in
g
,
a
lc
o
h
o
l
in
ta
k
e,
to
ta
l
ch
o
le
st
er
o
l
le
v
el
,
ca
rd
io
v
a
sc
u
la
r
d
is
ea
se
,
o
b
es
it
y
,
d
ia
b
et
es
m
el
li
tu
s.
O
R
=
o
d
d
s
ra
ti
o
;
C
I
=
co
n
fi
d
en
ce
in
te
rv
a
l;
S
B
P
=
sy
st
o
li
c
b
lo
o
d
p
re
ss
u
re
;
D
B
P
=
d
ia
st
o
li
c
b
lo
o
d
p
re
ss
u
re
;
A
E
R
=
a
lb
u
m
in
ex
cr
et
io
n
ra
te
.
1496 TAYLOR ET AL. SEPTEMBER 2013–VOL. 61, NO. 9 JAGS
significant primary effect on risk of dementia, with a
reduction in incidence from 7.7 to 3.8 per 1,000 person-
years,37 findings that persisted in open-label follow-up.42
In the current study sample, people receiving antihyperten-
sive treatment at baseline were more likely to have cogni-
tive impairment 20 years later, although antihypertensive
use at baseline reflects chronic exposure to hypertension as
well as its treatment. Overall, these findings may have
important clinical implications in terms of the importance
of detection and control of high BP in reducing the risk of
cognitive impairment later in life.
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